Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months.

25 Feb 2015

Researchers find that new targeted drugs can attack weak spots in cancer cells

Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs.

25 Feb 2015

Serous ovarian cancer is more deadly, shows Cancer Research UK study

THE most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a Cancer Research UK study published today (Tuesday) in PLOS Medicine.

25 Feb 2015

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Our research into gynaecological oncology focuses around understanding mechanisms of how genes are regulated or how they become dysregulated in a disease; and also the effects that has on the surface of the endometrium and also the function of the ovaries...

From Chromatrap® - Porvair Sciences Ltd 24 Feb 2015

Majority of women support idea of more frequent breast screening for individuals at higher risk of cancer

Most women (85 per cent) would back the idea of more frequent breast screening if they are at higher genetic risk of developing breast cancer, according to research published today by The Breast.

20 Feb 2015

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

17 Feb 2015

Wistar researchers identify new therapeutic target for aggressive form of ovarian cancer

Ovarian cancer is the deadliest of all cancers affecting the female reproductive system with very few effective treatments available. Prognosis is even worse among patients with certain subtypes of the disease. Now, researchers at The Wistar Institute have identified a new therapeutic target in a particularly aggressive form of ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease.

16 Feb 2015

New study finds promising target for future therapies to treat breast and ovarian cancer patients

The Food and Drug Administration's recent approval of the drug olaparib for ovarian cancer patients with inherited mutations in the genes BRCA1 or BRCA2 came as welcome news to the thousands of women now eligible to receive it. A new study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug is potentially much wider - and offers a ready means of identifying them.

16 Feb 2015

Risk of ovarian cancer increased with even short-term HRT use

There has been much uncertainty regarding the risk of cancer associated with taking hormone replacement therapy (HRT) for the menopause. An analysis of all available evidence published in The Lancet today shows that HRT, even when taken for only a few years, significantly increases the risk of developing the two most common types of ovarian cancer.

13 Feb 2015

Novel image-analysis technique improves breast cancer detection and diagnosis

Researchers at the University of Oklahoma have developed an image-analysis technique that is designed to improve breast cancer detection and diagnosis.

13 Feb 2015

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian cancer.

11 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Quest Diagnostics, Myriad Genetics reach agreement to end BRCA gene-patent litigation

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation.

From Quest Diagnostics 10 Feb 2015

Study links previously unknown genetic anomalies to breast cancer in African American family members

The "Jewels in our Genes" study, led by University at Buffalo researcher Heather Ochs-Balcom, has uncovered previously unknown segments of DNA shared by African American family members who have breast cancer. "The discovery of these regions supports our hypothesis that there are still undiscovered breast cancer genes that may be unique to African Americans," says Ochs-Balcom, PhD, a genetic epidemiologist in the UB Department of Epidemiology and Environmental Health.

10 Feb 2015

Bright Pink and David's Bridal team up to educate women on breast and ovarian cancer

As the nation's leading bridal and special occasion authority, David's Bridal is honored to outfit a woman for the many milestones in her life, most notably her wedding day.

6 Feb 2015

Research findings demonstrate new approach to transform behavior of tumor cells

Inserting a specific strain of bacteria into the microenvironment of aggressive ovarian cancer transforms the behavior of tumor cells from suppression to immunostimulation, researchers at Norris Cotton Cancer Center and the Geisel School of Medicine at Dartmouth have found.

5 Feb 2015

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

A University of Colorado Cancer Center study published in the journal PLoS One finds alterations in expression of genes PIK3R3 and PTEN, more commonly observed in adult tumors, in the rare, young-adult bone cancer Ewing Sarcoma, potentially offering ways to improve therapy.

4 Feb 2015

Oncology experts study use of fertility-sparing cancer treatments

While families around the world delay childbearing to later in life, cancer diagnoses are affecting people ever earlier in life. When these lifestyle trends collide, we see an increasing number of young women rendered infertile by cancer or cancer treatments.

4 Feb 2015

Research describes new way of shrinking ovarian cancer tumors, improving drug delivery

New research published in the February 2015 issue of The FASEB Journal, may eventually help improve the five-year survival rate of ovarian cancer patients by describing a new way of shrinking ovarian cancer tumors while also simultaneously improving drug delivery.

3 Feb 2015

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Janssen Research & Development, LLC announced today that the U.S. Food and Drug Administration has granted Priority Review for the New Drug Application (NDA) for YONDELIS (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

3 Feb 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

Researchers find that new targeted drugs can attack weak spots in cancer cells

Serous ovarian cancer is more deadly, shows Cancer Research UK study

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Majority of women support idea of more frequent breast screening for individuals at higher risk of cancer

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Wistar researchers identify new therapeutic target for aggressive form of ovarian cancer

New study finds promising target for future therapies to treat breast and ovarian cancer patients

Risk of ovarian cancer increased with even short-term HRT use

Novel image-analysis technique improves breast cancer detection and diagnosis

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

Quest Diagnostics, Myriad Genetics reach agreement to end BRCA gene-patent litigation

Study links previously unknown genetic anomalies to breast cancer in African American family members

Bright Pink and David's Bridal team up to educate women on breast and ovarian cancer

Research findings demonstrate new approach to transform behavior of tumor cells

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

Oncology experts study use of fertility-sparing cancer treatments

Research describes new way of shrinking ovarian cancer tumors, improving drug delivery

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in